Psychedelic microdosing

Latest Psilocybin Microdosing Study, Powered by Quantified Citizen, Finds Improved Mental Health and Psychomotor Performance in Those Over 55 Years of Age

Retrieved on: 
Monday, July 11, 2022
Psilocybin, Anxiety, Partnership, Trial of the century, Series, SXSW, Lion, Nature, Android, QC, TED, University, Maastricht University, Observational study, Mental health, Manuscript, Depression, Psychedelic microdosing, Mindfulness, IOS, GLOBE, Niacin, Growth, Pharmaceutical industry, Medical device, Mobile phone

The paper shows how psilocybin microdosing is associated with general improvements in mood and mental health.

Key Points: 
  • The paper shows how psilocybin microdosing is associated with general improvements in mood and mental health.
  • Additionally, a finding specific to individuals over the age of 55 indicated that microdosing was associated with greater improvements in psychomotor performance relative to non-microdosers.
  • Further, adults over 55 exhibited an even larger improvement in psychomotor performance when psilocybin is stacked with lion's mane and niacin ("Stamets Stack") compared to psilocybin alone.
  • To fuel further growth and development of new study capabilities, Quantified Citizen is currently in the process of raising its Series A round of funding.

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

Retrieved on: 
Tuesday, January 12, 2021
Health sciences, Life sciences, Health, Health informatics, Clinical research, Psychedelia, Nootropics, Psychedelic microdosing, Microdosing, Lysergic acid diethylamide, Psychedelic drug, Digital medicine

The study will provide an additional research pathway for MindMed's psychedelic Microdosing Division and will immediately integrate with MindMed's plans in digital therapeutics through its newly formed Albert unit for digital medicine.

Key Points: 
  • The study will provide an additional research pathway for MindMed's psychedelic Microdosing Division and will immediately integrate with MindMed's plans in digital therapeutics through its newly formed Albert unit for digital medicine.
  • MindMed is integrating innovative digital tracking devices and software into the study to better assess LSD's effects on various digital clinical markers on the human body.
  • In addition to this study, MindMed's Microdosing Division under the leadership of Dr. Halperin Wernli is undertaking a commercial Phase 2a Adult ADHD clinical trial evaluating microdoses of LSD.
  • The MindMed executive team brings extensive biopharmaceutical experience to the company's groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.